ulcer

Bio & Pharma HK inno.N releases new drug for GERD in Indonesia

South Korean bio-health company HK inno.N Corporation's new drug for gastroesophageal reflux disease (GERD) K-CAB has been officially launched in In...

Bio & Pharma HK inno.N's K-CAB to get insurance benefits in China

South Korea’s 30th novel medicine K-CAB Tab (active ingredient: tegoprazan), a gastroesophageal reflux disease (GERD) treatment of HK inno.N, ...

Bio & Pharma HK inno.N gets approval to sell K-CAB in Singapore

South Korean biohealth company HK inno.N said on Wednesday that it has received an item approval for K-CAB, a new drug for gastroesophageal reflux d...

Bio & Pharma New drug developer Onconic Therapeutics raises $20 mn in Series B

South Korean drug developer Onconic Therapeutics, announced on Friday that it raised 26 billion won ($19.9 million) in Series B funding, with cumula...

Bio & Pharma HK inno.N receives sales permit for ulcer treatment in China

HK inno.N is expediting its global expansion with its latest drug K-Cab designed to treat peptic ulcers.The South Korean pharmaceutical company an...